New Zealand - English - Medsafe (Medicines Safety Authority)

orion pharma (nz) limited - entacapone 200mg - film coated tablet - 200 mg - active: entacapone 200mg excipient: croscarmellose sodium ethanol glycerol hydrogenated vegetable oil hypromellose iron oxide red iron oxide yellow magnesium stearate   mannitol microcrystalline cellulose polysorbate 80 purified water sucrose titanium dioxide - entacapone is indicated as an adjunct to standard preparations of levodopa/benserazide or levodopa/carbidopa for use in patients with parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilized on those combinations.

Israel - English - Ministry of Health

inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - film coated tablets - levodopa 100 mg; carbidopa 25 mg; entacapone 200 mg - levodopa - levodopa - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

Israel - English - Ministry of Health

inovamed pharma ltd, israel - carbidopa as monohydrate; entacapone; levodopa - film coated tablets - carbidopa as monohydrate 18.75 mg; entacapone 200 mg; levodopa 75 mg - levodopa - levodopa - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa/decarboxylase (ddc) inhibitor treatment.

Israel - English - Ministry of Health

inovamed pharma ltd, israel - carbidopa as monohydrate; entacapone; levodopa - film coated tablets - levodopa 125 mg; entacapone 200 mg; carbidopa as monohydrate 31.25 mg - levodopa - levodopa - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa/decarboxylase (ddc) inhibitor treatment.

Israel - English - Ministry of Health

inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - film coated tablets - levodopa 50 mg; carbidopa 12.5 mg; entacapone 200 mg - levodopa and decarboxylase inhibitor - levodopa and decarboxylase inhibitor - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

Israel - English - Ministry of Health

inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - film coated tablets - levodopa 150 mg; carbidopa 37.5 mg; entacapone 200 mg - levodopa and decarboxylase inhibitor - levodopa and decarboxylase inhibitor - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

Ireland - English - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd t/a gerard laboratories - entacapone - film coated tablet - 200 milligram

Canada - English - Health Canada

glaxosmithkline inc - salbutamol (salbutamol sulfate) - solution - 0.5mg - salbutamol (salbutamol sulfate) 0.5mg - selective beta 2-adrenergic agonists

Canada - English - Health Canada

glaxosmithkline inc - salbutamol (salbutamol sulfate) - solution - 1mg - salbutamol (salbutamol sulfate) 1mg - selective beta 2-adrenergic agonists

Canada - English - Health Canada

sandoz canada incorporated - entacapone - tablet - 200mg - entacapone 200mg - catechol-o-methyltransferase (comt) inhibitors